PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2011
CASE
AUTH/2443/10/11 Genus Pharmaceuticals ⭐ Case of the Week

AUTH/2443/10/11: Anonymous v Genus Pharmaceuticals β€” conduct of Apo-go nurse advisor (No breach)

Anonymous pharmacist alleged an Apo-go nurse advisor changed Parkinson’s medicines without authority and failed to inform PDNSs. Panel found the programme a…

2018
CASE
AUTH/3069/9/18 Bayer

AUTH/3069/9/18: Director v Bayer β€” Clinical trial disclosure (EUCTR) (No breach)

BMJ trial-tracker data suggested 1 Bayer β€œdue” EUCTR trial lacked results (98.6% reported). Bayer showed the trial was withdrawn before enrolment and…

2018
CASE
AUTH/3082/9/18 Bristol-Myers Squibb

AUTH/3082/9/18: Director v Bristol-Myers Squibb (Clinical trial disclosure) – outwith scope of the Code

PMCPA case AUTH/3082/9/18 (Bristol-Myers Squibb) concerned clinical trial disclosure. The matter was ruled outwith the scope of the ABPI Code (Code year…

2018
CASE
AUTH/3118/11/18 Tesaro

AUTH/3118/11/18: Director v Tesaro β€” Clinical trial results posting on EUCTR (No breach on appeal)

BMJ analysis flagged a historic UK-site trial with results not posted to EUCTR by the EC guideline deadline. Panel found a Clause…

2012
CASE
AUTH/2474/1/12 GlaxoSmithKline

GSK employee complaint: Revolade IFR email implied off‑licence use; internal brand-plan email referenced off‑licence presurgery use (AUTH/2474/1/12)

PMCPA found breaches after a Revolade IFR appointment email implied use in myelofibrosis and an internal brand-plan email referenced off‑licence presurgery use…

2012
CASE
AUTH/2482/2/12 Novo Nordisk ⭐ Case of the Week

Novo Nordisk email invite to Diabetes UK symposium: consent wording for promotional emails not β€œabundantly clear” (AUTH/2482/2/12)

Anonymous complaint about a Novo Nordisk symposium invitation email. Most allegations were not upheld, but the opt-in wording for receiving promotional material…

2011
CASE
AUTH/2464/12/11 Novartis Pharmaceuticals UK

AUTH/2464/12/11: Healthcare journalist v Novartis – Galvus press release (no breach)

A journalist challenged a Galvus EU approval press release for implying β€œfew/limited treatment options” in renally impaired type 2 diabetes and citing…

2012
CASE
AUTH/2531/9/12 ProStrakan

ProStrakan: alleged misleading approach to book an appointment (AUTH/2531/9/12) – no breach

A consultant alleged a ProStrakan rep misled his secretary by implying they were working together on symptom control guidelines. Accounts conflicted and…

2013
CASE
AUTH/2577/2/13 AbbVie

AbbVie voluntary admission: out-of-date prescribing information used in Humira banner and journal ads (AUTH/2577/2/13)

AbbVie admitted Humira ads (online banner and journal print) used out-of-date prescribing information (May 2011) instead of the current Dec 2012 version.…

2012
CASE
AUTH/2542/11/12 Boehringer Ingelheim

AUTH/2542/11/12 & AUTH/2543/11/12: GP complaint about Trajenta promotional email to NHS address (No breach)

A GP complained that a Trajenta (linagliptin) advert was sent to his NHS email. The Panel found evidence he had opted in…

2013
CASE
AUTH/2592/4/13 GlaxoSmithKline ⭐ Case of the Week

GSK voluntary admission: Uncertified Benlysta case studies emailed to HCPs with broken PI link and misleading nephritis content (AUTH/2592/4/13)

GSK admitted two Benlysta promotional case studies were emailed to 48 HCPs before certification. Emails lacked integral prescribing information, had a broken…

2013
CASE
AUTH/2572/1/13 AstraZeneca

AUTH/2572/1/13: Ex-employee v AstraZeneca – archived investor presentations and Seroquel weight-gain claims (No breach)

Ex-employee alleged archived investor presentations (1999–2006) made false/imbalanced claims about Seroquel and weight. Panel and Appeal Board ruled no breach of Clause…

2013
CASE
AUTH/2616/7/13 Napp

Napp: BuTrans promotional emails sent without confirmed recipient permission via tele/e-detail agency (AUTH/2616/7/13)

Napp self-reported 3 BuTrans follow-up promotional emails sent after agency calls where consent to email was unclear. Panel found breach for one…

2013
CASE
AUTH/2648/10/13 Rosemont Pharmaceuticals

Rosemont voluntary admission: five sales staff lacked ABPI Medical Representatives Exam (AUTH/2648/10/13)

Rosemont disclosed that five long-standing sales staff did not sit the ABPI Medical Representatives Examination after an exemption ended in 2006. PMCPA…

2013
CASE
AUTH/2651/11/13 Merck Sharp & Dohme

AUTH/2651/11/13: Health professional complaint about alleged promotion of unlicensed pipeline medicines at ESGO stand (No breach) – Merck Sharp & Dohme

Anonymous health professional alleged MSD promoted unlicensed oncology pipeline medicines via exhibition panels at ESGO 2013. Panel had concerns (esp. trial recruitment…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training